583 related articles for article (PubMed ID: 11230485)
1. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
[TBL] [Abstract][Full Text] [Related]
2. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
[TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
4. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
[TBL] [Abstract][Full Text] [Related]
5. Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study.
Andersen MK; Christiansen DH; Pedersen-Bjergaard J
Genes Chromosomes Cancer; 2005 Apr; 42(4):358-71. PubMed ID: 15645489
[TBL] [Abstract][Full Text] [Related]
6. Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere.
Andersen MK; Pedersen-Bjergaard J
Leukemia; 2000 Jan; 14(1):105-11. PubMed ID: 10637484
[TBL] [Abstract][Full Text] [Related]
7. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J; Christiansen DH; Desta F; Andersen MK
Leukemia; 2006 Nov; 20(11):1943-9. PubMed ID: 16990778
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
[TBL] [Abstract][Full Text] [Related]
9. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
10. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Dissing M; Le Beau MM; Pedersen-Bjergaard J
J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
[TBL] [Abstract][Full Text] [Related]
11. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.
Merlat A; Lai JL; Sterkers Y; Demory JL; Bauters F; Preudhomme C; Fenaux P
Leukemia; 1999 Feb; 13(2):250-7. PubMed ID: 10025899
[TBL] [Abstract][Full Text] [Related]
13. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents.
Andersen MK; Christiansen DH; Kirchhoff M; Pedersen-Bjergaard J
Genes Chromosomes Cancer; 2001 May; 31(1):33-41. PubMed ID: 11284033
[TBL] [Abstract][Full Text] [Related]
14. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
Leukemia; 2003 Sep; 17(9):1813-9. PubMed ID: 12970781
[TBL] [Abstract][Full Text] [Related]
15. Translocations between the long arms of chromosomes 1 and 5 in hematologic malignancies are strongly associated with neoplasms of the myeloid lineages.
Johansson B; Brøndum-Nielsen K; Billström R; Schiødt I; Mitelman F
Cancer Genet Cytogenet; 1997 Dec; 99(2):97-101. PubMed ID: 9398862
[TBL] [Abstract][Full Text] [Related]
16. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
17. The p53 gene in pediatric therapy-related leukemia and myelodysplasia.
Felix CA; Hosler MR; Provisor D; Salhany K; Sexsmith EA; Slater DJ; Cheung NK; Winick NJ; Strauss EA; Heyn R; Lange BJ; Malkin D
Blood; 1996 May; 87(10):4376-81. PubMed ID: 8639798
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
Larson RA; Wang Y; Banerjee M; Wiemels J; Hartford C; Le Beau MM; Smith MT
Blood; 1999 Jul; 94(2):803-7. PubMed ID: 10397748
[TBL] [Abstract][Full Text] [Related]
19. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
